natgillin/translations-raw huggingface dataset:
The antibody for use according to any one of claims 1-7, wherein said subject's pre-administration absolute basophil count is about 5, about 10, about 15, about 20, about 25, about 30, about 50, about 60, about 70, about 100, about 200, about 300, about 400, or about 500 basophils/mm3. 
Protutijelo za upotrebu prema bilo kojem od zahtjeva 1 do 9, naznačeno time da navedeni subjekt ima apsolutni broj eozinofila prije davanja oko 25, oko 50, oko 75, oko 100, oko 125, oko 150, oko 175, oko 200, oko 225, oko 250, oko 275, oko 300, oko 325, oko 350, oko 375, oko 400, oko 450, oko 475, ili oko 500 eozinofila / mm3.
The first ring section 29 comprises vertical recesses 23 aligned with protruding portions or lugs 20 of the actuation member 17 so that these lugs 20 can pass trough the ring section 29 when depressing the actuation member 17 from the first position into the intermediate position. 
Prvi prstenasti dio 29 obuhvaća okomita udubljenja 23 poravnata sa stršećim dijelovima ili jezičcima 20 elementa za pokretanje 17 tako da ti jezičci 20 mogu proći kroz prstenasti dio 29 kad se element za pokretanje 17 pritisne iz prvog položaja u međupoložaj.
the safety bow comprises a horizontally arched crosspiece (41) with the two first ends (43) and connecting members (44), 
- < sigurnosni luk sadrži horizontalno postavljen poprečni dio (41) koji ima oblik luka sa dva prva kraja (43) i sa sredstvima za spajanje (44),
MgCl2, B-D-glucose-6-phosphate, BNADP and Glucose-6-phosphate dehydrogenase were used for preparing the NADPH regenerating solution (NRS). 
MgCl, fi-D-glukoza-6-fosfat, BNADP i Glukoza-6-fosfat dehidrogenaza rabljeni su za dobivanje NADPH regenerirajuće otopine (NRS).
of a 0.9% solution of sodium chloride, or of a 0.45% or 0.225% solution of sodium chloride, or of Ringer's solution and/or Ringer's lactate solution. 
0,9%-tne otopine natrijevog klorida; 0,45%-tne ili 0,225%-tne otopine natrijevog klorida; te Ringer-ove otopine i/ili Ringer-ove laktatne otopine; pri čemu spomenuti sastav ima pH vrijednost poželjno od 5 do 8, još bolje od 6,0 do 7,5.
TLC analysis (silica, ethyl acetate) showed that no alkene intermediate remained in the reaction mixture. 
TLC analiza (silicij, etil acetat) pokazuje da u reakcijskoj smjesi nije preostalo intermedijernog alkena.
The compositions of the invention will be conveniently formulated in the form of tablets that dissolve slowly in the oral cavity or chewing gums that release the active components slowly, mouthwashes, gels for dispersal in the oral cavity, or the like. 
Pripravci kako su navedeni u patentnim zahtjevima 1 do 7, naznačeni time da su u obliku tableta koje se polako otapaju u oralnoj šupljini ili guma za žvakanje koje polako oslobađaju aktivne tvari, vode za usta, gelova za disperziju u oralnoj šupljini i slično.
The method of embodiment 46, wherein the psychiatric disorder is bipolar disorder, schizophrenia, autism, Fragile X syndrome, or depression. 
psihijatrijski poremećaj; na primjer, bipolarni poremećaj, shizofrenija, depresija, posttraumatski stresni poremećaj; ili - poremećaj raspoloženja; ili -
A method of obtaining a sturgeon-derived oil wherein the oil is extracted from membrane of sturgeon roe sacks following separation of the roe from the roe sacks. 
Postupak dobivanja ulja koje potječe od jesetre, naznačeno time, da se ulje ekstrahira iz membrane jajnika jesetre poslije odvajanja ikre od jajnika.
deprotecting the compound of Formula XLV to give a compound of Formula XLVI; 
Formula XLVI oksidaciju spoja Formule XLVI, čime se dobiva spoj Formule XLVII:
X is a single bond, an oxygen atom, or a vinylene group; 
X predstavlja jednostruku vezu, atom kisika ili skupinu vinilena;
and the pharmacologically acceptable acid addition salts thereof. 
ili njegove farmakološki prihvatljive kiselinske adicijske soli.
The process according to claim 1, wherein the process is for manufacturing a compound selected from the group consisting of: 
Spoj sukladno bilo kojem od zahtjeva 1 do 11, odabrano iz skupine sastavljenu od slijedećih:
The content of piceatannol in terms of solid content is preferably 0.0001 to 99.9 mass%, more preferably 0.01 to 50 mass%, most preferably 0.1 to 10 mass%. 
Sastav koji sadrži piceatanol, prema bilo kojem od zahtjeva 1 do 5, naznačen time, da sastav sadrži piceatanol u količini od 0,1 do 10 masenih % u uvjetima krutog sadržaja.
F, G, H, K and L are, independently, selected from the group consisting of hydrogen, halogen, cyano, C1-4 alkyl, halosubstituted C1-4 alkyl, hydoxysubstituted:C1-4 alkyl, and C1-4 alkoxy; 
[image] F, G, H, K i L se neovisno bira iz skupine koju čine vodik, halogen, C1-4 alkil, halogenom supstituirani C1-4 alkil, hidroksi supstituirani C1-4 alkil i C1-4 alkoksi;
An L-malate salt having the formula: 
Sol L-malata koja sadrži formulu:
determining at least one transformation unit which is split from the coding unit using information about division for the at least one transformation unit, wherein the information about division for the at least one transformation unit is parsed from the bitstream, and 
određivanje barem jedne transformacijske jedinice koja je razdvojena iz jedinice kodiranja koristeći informaciju o transformacijskoj jedinici, pri čemu je informacija o transformacijskoj jedinici raščlanjena iz toka bitova;
7, 2 and 3; an antibody comprising a light chain variable domain of sequence SEQ ID No. 
7,213; b) antitijela koje sadrži varijabilnu domenu lakog lanca sekvencije SEQ ID br.
the at least one superfluidizing agent is from 0.1 to 2% by weight; 
(d) barem jedno sredstvo za superfluidiziranje je od 0,1 do 2% po masi;
The reconstituted formulation of claim 19, wherein acetate and trifluoroacetate each comprise less than 0.1% by weight of anions in the formulation. A method of preparing a formulation, comprising storing a lyophilized formulation according to claim 13 for at least a week at a temperature of at least 20° C.; and 
Postupak priprave formulacije, naznačen time što se sastoji u skladištenju liofilizirane formulacije u skladu s bilo kojim od patentnih zahtjeva 7-8 u trajanju od najmanje tjedan dana na temperaturi od najmanje 20 °C; i tako se dobije liofilizirana formulacija.
stripping said extracted phosphoric acid from said second organic solvent by an aqueous solution; and 
uklanjanje (283) spomenute ekstrahirane fosforne kiseline iz spomenutog drugog organskog otapala vodenom otopinom; i
The active compounds in the combination, i.e. the M3 antagonist of the invention, the B2-agonist, the corticosteroid and any other optional active compounds may be administered by any suitable route, depending on the nature of the disorder to be treated, e.g. orally (as syrups, tablets, capsules, lozenges, controlled-release preparations, fast-dissolving preparations, lozenges, etc); topically (as creams, ointments, lotions, nasal sprays or aerosols, etc); by injection (subcutaneous, intradermic, intramuscular, intravenous, etc.) or by inhalation (as a dry powder, a solution, a dispersion, etc). 
Djelatni spojevi u kombinacijama, tj. M3 antagonist sukladno predmetnom izumu, kortikosteroid i svi drugi izborni djelatni spojevi mogu se davati bilo kojom prikladnom rutom, ovisno o prirodi bolesti koja se liječi, npr. peroralno (u obliku sirupa, tableta, kapsula, pastila, pripravaka s nadziranim otpuštanjem, pripravaka s brzim otapanjem, pastila itd.); lokalno (u obliku krema, pomada, losiona, nazalnih sprejeva ili aerosola, itd.); uštrcavanjem (subkutano, intradermalno, intramuskularno, intravenski, itd.) ili inhalacijom (u obliku suhog praška, otopine, disperzije, itd.).
The polyalkylene oxide-adenosine deaminase conjugate of claim 7, wherein the polyethylene glycol is conjugated to the recombinant adenosine deaminase via a succinimidyl carbonate linker. 
Konjugat adenozin deaminaze i polialkilen oksida u skladu s patentnim zahtjevom 7, naznačen time, da je polietilen glikol konjugiran na rekombinantnu adenozin deaminazu preko sukcinimidil karbonat linkera.
The compounds of the invention may be administered as the sole active ingredient or in conjunction with, e.g. as an adjuvant to, other drugs e.g. immunosuppressive or immunomodulating agents or other anti-inflammatory agents, e.g. for use in the treatment or prevention of allo- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders, or a chemotherapeutic agent, e.g. a malignant cell anti-proliferative agent. 
Farmaceutska kombinacija, naznačena time, da obuhvaća terapeutski učinkovitu količinu spoja prema zahtjevu 1 ili 2, u kombinaciji s imunosupresivnim sredstvom, s protuupalnim sredstvom ili s kemoterapeutskim sredstvom. Spoj prema zahtjevu 1 ili 2, ili kombinacija prema zahtjevu 4, naznačen/a time, da se upotrebljava u liječenju ili prevenciji akutnog ili kroničnog odbacivanja transplantata alografta ili ksenografta, ili upalnih ili autoimunih poremećaja.
In some embodiments, the subject is an Apo E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, E4/E4 subject. In some embodiments, the subject is an Apo E3/E3 or E3/E4 subject. In some embodiments, the active agent is selected from the group consisting of acetylcholinesterase inhibitors, NMDA receptor antagonists, PPAR agonists or modulators (e.g., drugs in the thiazolidinedione or glitazar classes), antibodies, fusion proteins, therapeutic RNA molecules, and combinations thereof. 
Liječenje s učinkovitom količinom djelotvornog sredstva protiv Alzheimerove bolesti, koje je odabrano iz skupine koju čine: inhibitori acetilkolinesteraze, antagonisti receptora NMDA, agonisti ili modulatori receptora proliferativno aktiviranog peroksisoma (PPAR), protutijela, fuzijski proteini, terapeutske molekule RNK, te njihove kombinacije, za uporabu u postupku liječenja Alzheimerove bolesti, naznačeno time, da postupak liječenja obuhvaća korak određivanja da li je pojedinac u riziku za razvoj Alzheimerove bolesti ili nije, pri čemu se postojanje rizika utvrđuje postupkom prema bilo kojem zahtjevu od 1 do 3.
The method of claim 6, wherein the subsets to be generated is determined using a plurality of non-zero subset flags, and the subsets are generated by applying the inverse scan pattern to the significant flags, the coefficient signs and the coefficients levels. 
Postupak prema Zahtjevu 6, gdje se podskupovi koje je potrebno generirati određuju korištenjem oznake podskupa različitog od nule koji ukazuje da li podskup sadrži koeficijente različite od nule ili ne, 1 gdje su podskupovi generirani primjenom obrasca inverznog skeniranja na značajne oznake, znakove koeficijenata i razine koeficijenata.
Method of producing an IMP cell of the invention 
Datum objave europske prijave patenta:
The antisense oligonucleotide of claims 1-8, wherein the oligonucleotide is conjugated to a polyethylene glycol chain. 
Protusmisleni oligonukleotid ili njegova farmaceutski prihvatljiva sol prema zahtjevima 1-4, naznačen time što je oligonukleotid konjugiran na lanac polietilen glikola.
The first and second side together defines a cavity in which the element can be stored. 
Prva strana i druga strana zajedno određuju šupljinu u koju se može pohraniti element.
A process according to claim 11, wherein the reaction of the compound of formula (11) with an activated biphenylic compound takes place under Fe- or Mn-catalyzed cross coupling reaction conditions. 
35. Postupak prema zahtjevu 33 ili 34, naznačen time, da se reakcija spoja formule (11) s aktiviranim bifenilnim spojem, 5
The resulting light brown oil was dried under vacuum for 48h protected from the light using an aluminum foil. 
Nastala svijetlo smeđa hidrofobna tekućina suši se pod vakuumom 48 h, zaštićena od svijetla pomoću aluminijske folije.
represents a hydrogen atom, a C1-C6 alkyl group, or a halogen atom. 
R* predstavlja atom vodika, C,-Ce alkil grupu, ili atom halogena.
X is a leaving group selected from the group consisting of halogens, esters, sulfonates and phosphates; 
74. Spoj, naznačen time što ga se bira iz skupine koju čine:
(a6) shaking the bone marrow-containing container 40-50 times, (a7) centrifuging the shaken solution at 1,600 rpm for 4-5 minutes, and (a8) removing the supernatant from the centrifuged solution; 
(a6) protresanje spremnika koji sadrži koštanu srž od 40 do 50 puta; (a7) centrifugiranje protresane otopine na 1600 rpm u vremenu od 4 do 5 minuta; i (a8) odstranjivanje materijala koji je isplivao na površinu od centrifugirane otopine;
In general terms, a mechanical spring jar is a device included in a toolstring that when needed utilities the limited pull force available via the wireline to cock a mass against a spring, and subsequently release it so that the energy resulting from tensioning of the wireline drives the mass into a part of the toolstring. 
Promatrano općenito udarac s mehaničkom oprugom predstavlja uređaj koji se nalazi u alatu koji, kada je potrebno, koristi raspoloživu vučnu silu preko kabla da bi usmjerio masu nasuprot opruzi i subsekvetno je oslobodio, tako da energija koja potiče od napona kabla potiskuje masu u dio alata.
The process according to claim 18 or 19, wherein step (c) comprises thermal treatment, filtration, centrifugation, evaporation at reduced pressure, or any combination thereof. 
Postupak prema zahtjevu 5, naznačen time da korak (c) sadrži toplinsku obradu, filtraciju, centrifugiranje, ishlapljivanje kod sniženog pritiska, ili bilo koju njihovu kombinaciju.
Analytical LC-MS data were obtained by either of two methods: (method A): on a PE Sciex API 150EX instrument equipped with an IonSpray source and a Shimadzu LC-8A/SLC-10A LC system. 
EKSPERIMENTALNI DIO Analitički LC-MS podaci se dobivaju pomoću jedne od dviju metoda: (metoda A): u PE Sciex API 150EX instrumentu koji je opremljen s IonSpray izvorom i Shimadzu LC-8A/SLC-10A LC sistemom.
grinding, heating, co-subliming, co-melting, or contacting in solution the compound having the structure with 4-hydroxybenzoic acid under crystallization condition so as to form the co-crystal in solid phase, and 
1 ČHa s 4-hidroksibenzojevom kiselinom u uvjetima kristaliziranja, tako da nastane sukristal u čvrstoj fazi, i d) izborno izdvajanju sukristala nastalog u koraku (c).
Combination for use according to claim 1 where the daily dose of the leukotriene inhibitor is from 1 to 100 mg, preferably from 5 to 20 mg. 
Kombinacija za uporabu u skladu s patentnim zahtjevom 1, naznačena time, da je dnevna doza inhibitora leukotriena od 1 do 100 mg, poželjno od 5 do 20 mg.
The compounds of the present invention are preferably formulated prior to administration. Biological Assays 
Spojeve prema ovom izumu po mogućnosti se formulira prije primjene. Biološka ispitivanja
The mechanism according to claim 1, wherein one or more springs are linearly attached between at least one of said riders and the respective elongated element such that when said elongated element is tensioned above a predetermined threshold, the spring yields and further movement of said rider is no longer effective to tension said elongate element. 
Mehanizam prema zahtjevu 12, naznačen time da navedena spojka obuhvaća jednu ili više opruga učvršćenih između navedenih jahaćih elemenata i navedenih izduženih elemenata na način da, kad je izduženi element napet iznad praga, opruga propušta i daljnje kretanje jahaćeg elementa više nije učinkovito za poticanje pokreta navedenih izduženih elemenata.
The cores so obtained are then film-coated with an aqueous dispersion of acrylic and methacrylic acid esters, iron oxide, talcum and triethyl citrate, with confers on the product resistance to disintegration in an acidic environment, simulating the environment of the stomach and the small intestine. 
Tako dobivene jezgre obložene su filmom vodenim raspršenjem estera akrilnih i metakrilnih kiseline, željezo oksida, talka i trietil citrata, što produktu daje otpornost na razgradnju u jakom kiselinskom okolišu kao što je to okoliš želuca i tankog crijeva.
at least one component b4) and at least one component b5); and 
- barem jednu komponentu b4) i barem jednu komponentu b5); i
Des-alanyl-1, serine-125 forms of human IL-2 are particularly preferred for use with the invention. 
Des-alanil-1, serin-125 oblici humanog IL-2 su posebno pogodni za uporabu s izumom.
And wherein a processor (14) is further provided, configured to compare the coordinates received from the satellite with the ones contained in the memory so as to configure the monitor to the reception of the images of a specific sentinel apparatus in correspondence of the reaching of the train of the activation distance from the said sentinel apparatus and de-activating the monitor once the train has reached the de-activation point and the processor has recognized such a condition. 
- i pri čemu je dodatno predviđen procesor (14), konfiguriran za uspoređivanje koordinata primljenih od satelita s koordinatama sadržanim u memoriji tako da se konfigurira monitor za prijem slika za specifični nadzorni uređaj u skladu s nadolaskom vlaka na aktivacijsku udaljenost od navedenog nadzornog uređaja i deaktivaciju monitora nakon što je vlak stigao do de-aktivacijske točke i procesor je prepoznao takvo stanje.
Therefore, in a preferred embodiment, the antisense nucleotide sequence comprises at least one nucleotide analogue or equivalent, wherein a nucleotide analogue or equivalent is defined as a residue having a modified base, and/or a modified backbone, and/or a non-natural internucleoside linkage, or a combination of these modifications. 
Besmisleni oligonukleotid u skladu s patentnim zahtjevom 4, pri čemu je analog nukleotida definiran kao nukleotid koji ima modificiranu bazu, i/ili mdificiranu šećernu jedinicu i/ili modificiranu unutarnukleozidnu vezu.
Fig. 16 is a horizontal sectional view of a building wall as used in the building of Fig. 12. 
SL.16 je pogled vodoravnog presjeka zida građevine kakav je korišten u sl.12.
The human GDNF variant as claimed by Claim 1 wherein said variant is selected from the group consisting of and The human GDNF variant as claimed by Claim 2 wherein said variant is The human GDNF variant as claimed by Claim 2 wherein said variant is 
Varijanta ljudskog GDNF u skladu s patentnim zahtjevom 2, naznačena time što je navedena varijanta RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD KILKNLSRNRRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAK RCGCI (SEQ. ID: 9). Varijanta ljudskog GDNF u skladu s patentnim zahtjevom 2, naznačena time što je navedena varijanta RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD KILANLSKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAK RCGCI (SEQ ID NO: 12).
A pharmaceutical composition according to enbodiment 33, further comprising a pharmaceutically acceptable diluent or carrier. 
Farmaceutski sastav prema zahtjevu 18, naznačen time, da dodatno obuhvaća farmaceutski prihvatljiv razrjeđivač ili nosač.
According to a further embodiment, the hollow body is configured as a hollow cylinder, the upper edge and lower edge of which are aligned plane-parallel to one another in the axial direction. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je šuplje tijelo (HO) konstruirano kao šuplji valjak, čiji su gornji rub i donji rub međusobno poravnani planparalelno u aksijalnom smjeru.
A non-transitory storage medium which stores a speech decoding program executed by a computer device to decode an encoded speech signal, the speech decoding program causing the computer device to function as: 
Program za dekodiranje govora, namijenjen dekodiranju kodiranog govornog signala, naznačen time što omogućuje da kompjutorska naprava funkcionira kao:
A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt or N-oxide derivative thereof, and a pharmaceutically acceptable carrier or diluent. 
Farmaceutski sastav sadrži terapijski učinkovitu količinu tvari iz bilo kojeg od prethodnih patentnih zahtjeva ili ili farmaceutski prihvatljivu sol ili njen N-oksid derivat, i farmaceutski prihvatljivi nosač ili diluent.
a series of steps of defining the connected devices that are directly supplied with water by said flow rate sensor and allowing the logic processing unit to execute the following algorithm: record in a first list an electric valve; record in a second list a flow rate sensor; 
• niz koraka (11-4) za definiranje uređaja spojenih izravno na dovod vode pomoću navedenog senzora protoka i omogućavanje jedinici za logičku obradu da izvršava sljedeći algoritam o ako povezani uređaj obuhvaća električni ventil, potonji je registriran na prvom popisu koji se naziva ov;
Method according to claim 3, wherein the medium is recycled from the second device towards the first device, for cooling of the first device, and wherein the medium is cooled during the recycling. 
Postupak prema zahtjevu 3, 4 ili 5, naznačen time da se medij reciklira od drugog uređaja prema prvom uređaju, radi hlađenja prvog uređaja, te time da se prije recikliranja medij hladi.
If a leak occurs in one or more of the tubes, the chemical substance, which is capable of changing the electrical conductivity of the cooling medium, will seep into the medium circulating in the tube's cooling jacket, along with the other chemical substances present in the inner tubes. 
Metoda upravljanja uređajem za visokotlačnu polimerizaciju etilena koji sadrži tubularni reaktor, naznačena time što je svojstvo metode da se električna vodljivost rashladnog medija koji za rashlađivanje koristi vodu, a koji cirkulira kroz jedan ili više rashladnih krugova tubularnog reaktora, nadzire na najmanje jednoj lokaciji.
The pneumatic speargun as claimed in claim 1, wherein said continuous or discontinuous slide guide (2) is located at a top of said cylinder (1). 
Podvodna puška u sukladu sa zahtjevom 1, pri čemu se spomenuta kontinuirana ili diskontinuirana klizna vodilica (2) nalazi na vrhu cilindra (1).
A method according to claim 1, wherein the heat recovery steam generator (7) produces steam with a temperature higher than 400°c and pressure higher than 35 bars-absolute and the steam turbine is a high-pressure turbine. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da parogenerator na principu oporavka topline (7) proizvodu paru temperature više od 400°C, apsolutnog tlaka višeg od 35 bara, a parna turbina je visokotlačna turbina.
In one aspect, the invention provides that the synthetic intron is located between the nucleic acid encoding for the VH domain and the nucleic acid encoding for the Fc or the hinge of the antibody, between the nucleic acid encoding for the CH2 and the CH3 domain of the antibody, between the nucleic acid encoding for the hinge region and the CH2 domain of the antibody. 
Molekula nukleinske kiseline prema patentnom zahtjevu 4, naznačena time, da je sintetički intron smješten između nukleinske kiseline koja kodira za CH2 i CH3 domenu protutijela ili time, da je sintetički intron smješten između nukleinske kiseline koja kodira za spojnu regiju i domenu CH2 protutijela.
identifying the patient in need of therapy for the proliferative disease; and administering to the patient in need of such treatment a therapeutically effective amount of Crenolanib or a salt thereof, wherein the cell proliferative disorder is characterized by deregulated FLT3 receptor tyrosine kinase activity, wherein the proliferative disease is a hematological malignancy selected from at least one of a leukemia, myeloma, myeloproliferative disease, myelodysplastic syndrome, idiopathic hypereosinophilic syndrome (HES), and a hematologic malignancy. 
Pripravak koji sadrži terapeutski djelotvornu količinu crenolaniba ili njegove soli namijenjen uporabi u liječenju FL T3 mutirane akutne mijeloične leukemije (AML) kod subjekta, pri čemu spomenuto liječenje obuhvaća; ispitivanje uzorka od subjekta; određujući iz predmetnog uzorka da subjekt ima deregulirani FLT3 receptor tirozin kinaze; 1 davanje subjektu terapeutski djelotvorne količine crenolaniba ili njegove soli ako je leukemija karakterizirana dereguliranom aktivnošću FLT3 receptorske tirozin kinaze, pri čemu je subjekt osoba.